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1571Overview of the 2011 Food and Drug Administration’s Meeting
on the CardioMEMS Champion Heart Failure Monitoring SystemJoshua P. Loh, Israel M. Barbash, Ron Waksman
The CardioMEMS Champion Heart Failure (HF) Monitoring System is a permanently
implantable pressure measurement system designed to wirelessly measure and report
pulmonary artery pressure and heart rate in HF patients with the goal of improving
ambulatory HF management and reducing HF hospitalizations. The Food and Drug
Administration’s Circulatory System Device Panel reviewed the pre-market approval
application where it was not approved. Loh and colleagues review the discussions and
recommendations made during this meeting, including the concern among panel members
that subjects with the device may have received preferential support from the lead
investigators. The majority of Panel members decided that there was not reasonable assurance
that the discussed monitoring system is effective at improving ambulatory HF management.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
1577Transcatheter Aortic Valve Implantation for
Pure Severe Native Aortic Valve RegurgitationDavid A. Roy, Ulrich Schaefer, Victor Guetta, David Hildick-Smith, Helge Moellman, Nicholas Dumonteil,
Thomas Modine, Johan Bosmans, Anna Sonia Petronio, Neil Moat, Axel Linke, Cesar Moris,
Didier Champagnac, Radoslaw Parma, Andrzej Ochala, Diego Medvedofsky, Tiffany Patterson,
Felix Woitek, Marjan Jahangiri, Jean-Claude Laborde, Stephen J. Brecker
Roy and colleagues collected data from 14 centers performing transcatheter aortic valve
implantation (TAVI) to its anecdotal use for patients with pure native aortic valve
regurgitation (NAR) deemed inoperable. A total of 43 patients had severe NAR without
aortic stenosis. Nearly 20% required a second valve during the index procedure for residual
aortic regurgitation (AR). In all cases requiring second valves valvular calcification was absent.
Post-procedure AR  grade I was present in 79% of patients. At 30 days, major stroke
incidence was 4.7%, and all-cause mortality was 9.3%. This study demonstrates the feasibility
and potential procedural difficulties of treating patients with TAVI for severe NAR.(continued on page A-26)
APRIL 16, 2013 (continued) A-26INTERVENTIONAL CARDIOLOGY1585Incidence, Predictors, and Outcomes of Aortic Regurgitation After TAVRGanesh Athappan, Eshan Patvardhan, E. Murat Tuzcu, Lars Georg Svensson, Pedro A. Lemos,
Chiara Fraccaro, Giuseppe Tarantini, Jan-Malte Sinning, Georg Nickenig, Davide Capodanno,
Corrado Tamburino, Azeem Latib, Antonio Colombo, Samir R. Kapadia
Athappan and colleagues analyzed the published literature to establish the incidence, impact,
and predictors of aortic regurgitation (AR) after transcatheter aortic valve replacement
(TAVR). A total of 45 studies reporting on 12,926 patients (CoreValve, n  5,261; Edward’s
valve, n  7,279) were included in the analysis. The pooled estimate for significant AR
(moderate and severe) post-TAVR was 11.7%. Significant AR was more common with use
of the CoreValve (16.0% vs. 9.1%). The presence of significant AR was associated with
increased mortality at 30 days (odds ratio: 2.95). Significant AR after TAVR is common and
associated with increased mortality.INTERVENTIONAL CARDIOLOGY1596Safety and Feasibility of Robotic PCIGiora Weisz, D. Christopher Metzger, Ronald P. Caputo, Juan A. Delgado, J. Jeffrey Marshall,
George W. Vetrovec, Mark Reisman, Ron Waksman, Juan F. Granada, Victor Novack, Jeffrey W. Moses,
Joseph P. Carrozza
The PRECISE study evaluated the safety and effectiveness of robotic-assisted percutaneous
coronary intervention (PCI) performed with the CorPath 200 robotic system. This system
consists of a remote interventional cockpit and a bedside disposable cassette that enables the
operator to advance, retract, and rotate guidewires and catheters. A total of 164 patients were
enrolled at 9 sites, and PCI was completed successfully without conversion to manual
operation in 99%. There were no device-related complications. Radiation exposure for the
primary operator was estimated to be 95% lower than the levels found at the traditional table
position. This multi-center study suggests that robotic-enhanced PCI may safely reduce
operator radiation exposure and reduce some of the physical strain on the operator associated
with performing PCI.(continued on page A-27)
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1601Comparison of Prasugrel and Ticagrelor Loading
Doses on Platelet Reactivity in STEMI PatientsGuido Parodi, Renato Valenti, Benedetta Bellandi, Angela Migliorini, Rossella Marcucci, Vincenzo Comito,
Nazario Carrabba, Alberto Santini, Gian Franco Gensini, Rosanna Abbate, David Antoniucci
Parodi and colleagues compared the onset of action of prasugrel and ticagrelor in ST-segment
elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary
intervention (PPCI). A total of 50 patients with STEMI undergoing PPCI with bivalirudin
monotherapy were randomized to receive 60-mg prasugrel loading dose (LD) or 180-mg
ticagrelor LD. Residual platelet reactivity was assessed by VerifyNow at baseline and 2, 4, 8,
and 12 h after LD. Using a noninferiority study design, platelet reactivity units (PRU) 2 h
after the LD were similar. High residual platelet reactivity (PRU 240) was found in 44%
and 60% patients at 2 h treated with prasugrel and ticagelor, a difference that was not
statistically different. These results show nonsignificant differences in onset of action of
prasugrel and ticagrelor for PPCI in STEMI patients.CORONARY ARTERY DISEASE
1607Low Rates of Optimal Risk Factor Control for
CAD Secondary Prevention in Large Randomized TrialsMichael E. Farkouh, William E. Boden, Vera Bittner, Victoria Muratov, Pamela Hartigan, May Ogdie,
Marnie Bertolet, Shiny Mathewkutty, Koon Teo, David J. Maron, Sanjum S. Sethi, Michael Domanski,
Robert L. Frye, Valentin Fuster
Farkouh and colleagues evaluated data from 3 large trials that focused on optimal medical
therapy (OMT) to determine if formalized attempts at risk factor control are effective in
achieving treatment goals for diabetic patients with coronary artery disease (CAD). The
percentage of patients achieving the target low-density lipoprotein increased from 55% at
baseline to 77% after 1 year in the COURAGE study, from 59% to 75% in the BARI 2D
study, and from 34% to 42% in the FREEDOM study. While similar improvements were
seen for systolic blood pressure, glycemic control, and smoking cessation, only 8% to 23% of
subjects met all 4 pre-specified treatment targets at 1-year follow up.(continued on page A-28)
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1616No Benefit to Repeat Myocardial Revascularization in
Patients With Silent Ischemia After Previous RevascularizationNael Aldweib, Kazuaki Negishi, Rory Hachamovitch, Wael A. Jaber, Sinziana Seicean, Thomas H. Marwick
Aldweib and colleagues sought to determine the benefit of myocardial perfusion imaging and
subsequent revascularization, for asymptomatic patients who have previously undergone
revascularization. Of the 6,750 patients with previous revascularization undergoing myocardial
perfusion scintigraphy, 769 patients had ischemia and were asymptomatic; 15% underwent
revascularization. There was no difference in all-cause death among those with
ischemia who were revascularized and those treated with medical therapy. After
adjusting for baseline characteristics, type of prior revascularization, MPS data, and
propensity scores, only age and hypercholesterolemia, but not revascularization, were
associated with mortality. Asymptomatic patients with prior revascularization and
inducible ischemia on MPS realize no survival benefit from repeat revascularization.Editorial Comment: David J. Maron, Judith S. Hochman, p. 1624BIOMARKERS
1626Microalbuminuria Is Linearly Associated With
the Risk of Death Except in Patients With CKDCsaba P. Kovesdy, Evan H. Lott, Jun Ling Lu, Sandra M. Malakauskas, Jennie Z. Ma, Miklos Z. Molnar,
Kamyar Kalantar-Zadeh
Kovesdy and colleagues examined the association of urine microalbumin-creatinine ratio
(UACR) with mortality and estimated glomerular filtration rate (eGFR) in a nationally
representative cohort of U.S. veterans. UACR was linearly associated with all-cause mortality
in all subgroups, except for those with CKD who had a U-shaped association with higher
mortality at very low levels. These data suggest that proteinuria-lowering interventions in
patients with advanced CKD should be implemented cautiously, and the authors speculate
that low renal perfusion pressure may explain the findings.Editorial Comment: Carmine Zoccali, Francesca Mallamaci, p. 1634YEAR IN CARDIOLOGY SERIES YEAR IN CARDIOLOGY SERIES1637Year in Interventional CardiologySimon R. Dixon, Robert D. Safian
Dixon and Safian review the major scientific work published or presented as a late-breaking
trial in 2012 that relates to interventional cardiology. The paper provides a broad overview for
general cardiologists, as well as a framework for more detailed study for those interested in
interventional cardiology.
